|
Miraculins Inc., a biotechnology company dedicated to the discovery and development of diagnostic tools and therapeutic products for cancer, is pleased to announce that it has reached an agreement with Diagnos Inc.(TSX-V:ADK), a leader in the use of artificial intelligence (AI) and advanced knowledge extraction techniques, to provide services towards the development of Miraculins’ cancer diagnostic discovery programs.
Read More
|
|
Miraculins Inc., a biotechnology company, dedicated to the discovery and development of diagnostic tools and therapeutic products for cancer, is pleased to announce that it is filing today, a pre-IDE (Investigational Device Exemption) submission with the U.S. Food and Drug Administration (FDA), in preparation for its planned clinical study for its P2V™ prostate cancer diagnostic test.
Read More
|
|
Miraculins Inc., a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, is pleased to announce that Mr. Eric Johnstone, CA has been appointed as Chief Financial Officer.
Read More
|
|
Miraculins Inc., a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, is pleased to announce that it will be presenting at AACR-NCI-EORTC International Conference: “Molecular Targets and Cancer Therapeutics” to be held on October 22 - 26, 2007, in San Francisco, CA.
Read More
|
|
Miraculins Inc., a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, is pleased to update the Company’s shareholders on its prostate cancer diagnostic.
Read More
|
|
|